BAYHILL THERAPEUTICS - Additional Technologies

Protein Arrays
Protein array technology provides precise analysis of the antigen targets in autoimmune diseases. Bayhill plans to use the technology in guiding product development and to enter licensing arrangements for diagnostic applications.

Reverse Proteomics
Reverse proteomics was developed by Bayhill’s founders as a technology platform for validating and discovering therapeutic targets. Reverse proteomics involves probing arrays of immobilized autoantigens with patient serum to select specific autoantigens. Autoantigens selected through reverse proteomics can be included in a specific autoantigen encoding plasmid, or in drug monitoring, clinical research and eventually diagnostics. The inclusion of these newly defined self-antigens within Bayhill’s BHT-DNA™ program allows for the development of antigen specific therapies to benefit the treatment of autoimmune diseases.

Toll-like Receptor Inhibitors
Bayhill has identified short DNA sequences that inhibit specific members of the Toll-like receptor family. The activity of these receptors is associated with a number of autoimmune and inflammatory diseases and targeting of TLRs represents a novel approach to autoimmune disease therapy. Bayhill’s TLR inhibitors have been evaluated in vitro using cells from healthy donors and autoimmune patients and the immunoregulatory activity of these compounds has been validated in multiple animal models of autoimmune disease.